# Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia

> **NCT06826430** · PHASE1 · RECRUITING · sponsor: **Juventas Cell Therapy Ltd.** · enrollment: 12 (estimated)

## Conditions studied

- Autoimmune Thrombocytopenia

## Interventions

- **DRUG:** Inaticabtagene autoleucel Injection

## Key facts

- **NCT ID:** NCT06826430
- **Lead sponsor:** Juventas Cell Therapy Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2026-03-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06826430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06826430, "Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06826430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*